These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25869767)

  • 1. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
    Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
    AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
    Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
    J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.
    Glassman PM; Balthasar JP
    MAbs; 2017; 9(2):297-306. PubMed ID: 27892793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
    Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.